RxDoctor Payments Data

Anthony D Agostino, MD

Internal Medicine · Naples, FLNPI 1679644595

Payments from drug & device makers

$777in general payments, 2019–2025

Across 43 payments — averaging $18.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Kowa Pharmaceuticals America, Inc.$183
  • Pfizer$182
  • Johnson & Johnson$166
  • GSK$83
  • Amarin Pharma, Inc.$22
  • Novo Nordisk$22
  • plus $119 from 7 others

What the payments were for

  • Food & beverage$777100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$777 in reported general payments places this provider in the 65th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$311,282
Medicare patients
491
Services billed
4,135

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban126$153,182
XareltoRivaroxaban39$59,958
OzempicSemaglutide42$52,367
JardianceEmpagliflozin37$49,565
MounjaroTirzepatide26$34,184
JanuviaSitagliptin Phosphate16$26,842
Breo ElliptaFluticasone/Vilanterol42$21,425
Trelegy ElliptaFluticasone/Umeclidin/Vilanter21$16,114
MyrbetriqMirabegron11$14,528
Repatha SureclickEvolocumab17$14,492
Janumet XrSitagliptin Phos/Metformin Hcl11$12,447
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr14$8,109
SynthroidLevothyroxine Sodium90$7,858
Spiriva RespimatTiotropium Bromide12$6,220
Metoprolol Succinate308$4,657

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$182$153,182126 claims
Johnson & JohnsonXarelto$166$59,95839 claims
Boehringer IngelheimJardiance, Spiriva Respimat$19$55,78549 claims
Novo NordiskOzempic$22$52,36742 claims
GSKBreo Ellipta, Trelegy Ellipta, Anoro Ellipta$83$45,64877 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Naples

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →